Genetic deletions or mutations that abrogate the DNA binding capacity of TP53 occur in 70% of cases of human PDAC, and TP53 mutations are associated with high-grade pancreatic intraepithelial neoplasia (PanIN) lesions and carcinoma in situ [8,9]. This evidence concerns the gene TP53 and in situ carcinoma.